Drug intelligence / Profile preview

IVA-mAb

Development stage: Preclinical
Lead developer: IDBiologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

IVA-mAb is a monoclonal antibody developed by IDBiologics for the treatment and prevention of Influenza A virus (IAV) infections. It is designed to neutralize a broad range of IAV strains, including seasonal variants and pandemic-potential strains such as H1N1, H3N2, H5N1, and H7N9. The antibody is part of IDBiologics' infectious disease portfolio and is intended to be used either as a standalone therapy or as part of a combination 'Pan-Influenza' regimen alongside IVB-mAb to provide protection against both Influenza A and B viruses. The mechanism of action involves binding to and neutralizing the virus, thereby preventing viral entry into host cells and reducing viral replication.

Beyond the preview

Go deeper on IVA-mAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVA-mAb.

Explore the full profile